

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



OrbusNeich Medical Group Holdings Limited

業聚醫療集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6929)

GRANT OF SHARE OPTIONS

This announcement is made pursuant to Rules 17.06A, 17.06B and 17.06C of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

On July 10, 2023, OrbusNeich Medical Group Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) granted a total of 6,172,000 share options (the “**Share Options**”) to eligible grantees (the “**Grantees**”), subject to acceptance of the Grantees, to subscribe for a total of 6,172,000 ordinary shares of US\$0.0005 each of the Company (the “**Shares**”) under the share option scheme of the Company adopted on December 5, 2022 (the “**Post-IPO Share Option Scheme**”). Details of the Share Options granted are as follows:

Date of grant	July 10, 2023
Exercise price of the Share Options granted	HK\$9 per Share, being at least the higher of: (i) the closing price HK\$8.57 per Share as stated in the Stock Exchange’s daily quotations sheet on the date of grant; and (ii) the average closing price of HK\$8.706 per Share as stated in the Stock Exchange’s daily quotations sheets for the five business days immediately preceding the date of grant
Number of Share Options granted	6,172,000
Closing price of the Shares on the date of grant	HK\$8.57 per Share

Exercise period of the Share Options	The option period of the Share Options shall be ten years from the date of grant (the “ Option Period ”) and the Share Options shall lapse at the expiry of the Option Period.
Vesting period of the Share Options	<p>The Share Options shall be vested in four tranches:</p> <ul style="list-style-type: none"> (i) 25% shall be vested on the first anniversary of the date of grant and be exercisable at any time during the period from the first anniversary of the date of grant to the end of the Option Period; (ii) 25% shall be vested on the second anniversary of the date of grant and be exercisable at any time during the period from the second anniversary of the date of grant to the end of the Option Period; (iii) 25% shall be vested on the third anniversary of the date of grant and be exercisable at any time during the period from the third anniversary of the date of grant to the end of the Option Period; and (iv) 25% shall be vested on the fourth anniversary of the date of grant and be exercisable at any time during the period from the fourth anniversary of the date of grant to the end of the Option Period.
Performance target	There is no performance target attached to the Share Options.
Clawback mechanism	The Share Options granted were subject to clawback mechanism as set out in the terms of the Post-IPO Share Option Scheme, in particular, the lapse of Share Options upon cessation of employment of the Grantees on the grounds such as he/she has been guilty of serious misconduct or has been convicted of any criminal offence involving his/her integrity or honesty.
Number of Shares available for future grants	Upon the grant of Share Options, the number of Shares available for future grants under the Post-IPO Share Option Scheme is 76,604,993 Shares.
Financial assistance	The Group did not provide any financial assistance to the Grantees to facilitate their purchase of Shares under the Post-IPO Share Option Scheme.

All Share Options are granted to employees of the Group.

To the best of the Directors' knowledge, information and belief after having made all reasonable enquiries: as at the date of this announcement, (i) none of the Grantees is a Director, chief executive or substantial shareholder of the Company or an associate (as defined under the Listing Rules) of any of them; (ii) none of the Grantees is a participant with Share Options granted and to be granted in any 12-month period exceeding the 1% individual limit under the Listing Rules; and (iii) none of the Grantees is a related entity participant or service provider (as defined under the Listing Rules).

By order of the Board
OrbusNeich Medical Group Holdings Limited
Mr. David CHIEN
Chairman, Executive Director and Chief Executive Officer

Hong Kong, July 10, 2023

As at the date of this announcement, the Board comprises Mr. David CHIEN, Ms. Kwai Ching Denise LAU, Mr. Wing Shing CHEN and Mr. Ching Chung John CHOW as Executive Directors; Dr. Yi ZHOU and Mr. Ting San Peter Lionel LEUNG as Non-Executive Directors; and Mr. Yip Keung CHAN, Mr. Ka Keung LAU BBS, MH, JP and Dr. Lai Fan Gloria TAM as Independent Non-executive Directors.